Table 1.
Unadjusted Characteristics of the Study Population *
| Variable | ||||
|---|---|---|---|---|
| Escitalopram | Citalopram | Sertraline | P Value |
|
| (n=1,520) | (n=1,559) | (n=1,356) | ||
| Female, % | 73.2 | 68.7 | 72.1 | 0.015 |
| Race, % | ||||
| Non-Hispanic White |
92.8 | 92.8 | 92.1 | 0.727 |
| Black | 3.3 | 3.5 | 3.6 | 0.893 |
| Other Races | 3.9 | 3.7 | 4.3 | 0.744 |
| Age | 75.0±0.3 | 74.3±0.3 | 74.2±0.3 | 0.100 |
| LIS, % | 19.7 | 21.7 | 21.0 | 0.353 |
| Prescription drug risk score, mean |
0.70±0 | 0.71±0 | 0.71±0 | 0.191 |
| No. Elixhauser comorbidities, mean |
3.17±0.07 | 2.90±0.06 | 3.05±0.07 | 0.015 |
| Diagnosed chronic conditions in prior year, % | ||||
| Depression | 46.6 | 36.7 | 40.4 | <0.01 |
| Alzheimer's | 11.2 | 9.8 | 9.1 | 0.150 |
| Heart Failure | 22.5 | 20.4 | 22.3 | 0.288 |
| COPD | 12.3 | 12.9 | 15.9 | 0.011 |
| Diabetes | 26.2 | 27.2 | 28.1 | 0.539 |
| RA/OA | 29.3 | 27.3 | 28.2 | 0.459 |
*
Plus-minus values are means±SE.
Abbreviations: LIS = low income subsidies, this group includes duals and non-duals with low-income subsides for Part D; COPD = Chronic obstructive pulmonary disease; RA/OA = Rheumatoid arthritis/osteoarthritis.